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Abstract
Background: Furosemide is commonly prescribed in critically ill patients with acute kidney injury (AKI). Existing
data from observational studies and small clinical trials have significant limitations and have reported conflicting
findings. There remains controversy on whether furosemide can impact clinical outcomes in critically ill patients
with AKI; however, a survey of intensivists and nephrologists showed equipoise for high-quality evidence on this
important issue.
Design/Methods: This protocol summarizes the rationale and design of a phase II randomized, blinded, placebo-
controlled trial of a low-dose continuous infusion of furosemide, titrated to the physiology parameter of urine
output, in critically ill patients with early AKI. Two hundred sixteen adult critically ill patients with early evidence of
AKI, defined by the RIFLE criteria, will be enrolled. Included patients will also have fulfilled ≥2 criteria of the
systemic inflammatory response syndrome and achieved immediate goals of acute resuscitation. The primary
outcome is progression in severity of kidney injury. Secondary outcomes include: safety, fluid balance, electrolyte
balance, the need for renal replacement therapy, duration of AKI, rate of renal recovery, mortality and changes in
novel serum and urine biomarkers of AKI. The primary analysis will be intention-to-treat. Planned recruitment will
be complete by June 2011 and results available by December 2011.
Trial Registration: ClinicalTrials.gov Identifier NCT00978354
Background
Acute kidney injury (AKI) is common and increasingly
encountered in hospitalized patients [1-3]. An estimated
6% of critically ill patients admitted to intensive care
(ICU) develop severe AKI, and approximately 70% even-
tually receive acute renal replacement therapy (RRT)[4].
Moreover, critical illness complicated by AKI remains
associated with high morbidity, mortality and health
resource use [4-11].
There are few, if any, interventions proven to impact
on the clinical course and outcome for critically ill
patients once AKI is established[12,13]. However,
important questions remain regarding the supportive
role of selected interventions that still demand higher-
quality evidence and better characterization in
randomized trials to evaluate their impact in AKI. One
example is: what is the role for loop diuretics, specifi-
cally furosemide, in the management of critically ill
patients with early AKI?
Furosemide acts at the medullary thick ascending loop
of Henle to inhibit the Na+/K+/Cl- pump on the lumi-
nal cell membrane surface and can theoretically reduce
renal tubular oxygen demand[14,15]. Experimental data
have also suggested low-dose furosemide infusion may
attenuate ischemia/reperfusion-induced apoptosis and
associated gene transcription in AKI[16,17]. These data
support the hypothesis that the timely administration of
furosemide may attenuate and/or reduce the severity of
early onset AKI. In addition, furosemide may also have
an important adjuvant role for maintaining fluid home-
ostasis and for optimal delivery of nutrition in critically
ill AKI patients[18,19].
Furosemide remains the most common loop diuretic
prescribed in critically ill patients[20]. In the BEST
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>1700 critically ill patients with AKI, 70% had received
diuretics at the time of enrollment, of whom 98% were
receiving furosemide[21]. While numerous studies have
evaluated loop diuretics in the treatment of AKI [22-30],
the majority have failed to find consistent clinical bene-
fit. Moreover, two large observational studies of AKI in
critically ill patients have reported discrepant findings
on the effect of loop diuretics on mortality and renal
recovery[21,31]. Additional small trials have suggested
that diuretics may reduce the severity of kidney injury
by converting “oliguric” to “non-oliguric” AKI, shorten
the duration of AKI, improve the rate of renal recovery,
and perhaps delay or ameliorate need for RRT
[22,24,32-35]. However, improvements in survival or
renal recovery have yet to be confirmed with high-qual-
ity evidence. Accordingly, there is controversy as to
whether furosemide can impact clinical outcomes and
should be used in critically ill patients with AKI [36-40].
A recent systematic review of randomized trials asses-
sing the role of loop diuretics in AKI found five trials
enrolling 555 patients that focused on critically ill
patients[41]. This review found no statistical difference
in mortality (odds ratio [OR], 1.28, p = 0.18) or renal
recovery (OR, 0.88, p = 0.5) for use of loop diuretics
compared with control. However, loop diuretics were
associated with a shorter duration of RRT (weighted
mean difference, -1.4 days, p = 0.02), shorter time to
spontaneous decline in serum creatinine (weighted
mean difference, -2.1 days, p = 0.01) and a greater
increase in urine output from baseline (OR, 2.6,
p = 0.004). There was insufficient data to comment on
the impact of loop diuretics on electrolyte abnormalities,
fluid balance, duration of mechanical ventilation,
secondary organ dysfunction, hospital length of stay or
health costs.
Importantly, however, this review found that the over-
all trial quality and applicability of this evidence to criti-
cally ill patients was poor[41]. For example, trials were
generally small, confounded by co-interventions (i.e.
mannitol, dopamine), and characterized by delayed or
late intervention (i.e. prolonged periods of oligo-anuria
or already receiving RRT at the time of enrollment).
Finally, these trials often administered furosemide as
large intravenous bolus doses with no specific titration
of therapy to physiologic endpoints such as urine out-
put. As a consequence, these data have limited applic-
ability to modern critically ill patients and to current
ICU practice.
A recent multi-national survey of intensivists and
n e p h r o l o g i s t ss h o w e dt h a tm o s tr e s p o n d e n t sd i dn o t
believe that furosemide use in AKI would directly
improve outcomes such as mortality, need for RRT, or
renal recovery[20]. However, there was significant
uncertainty about the existing evidence and the majority
had equipoise for and supported a trial on this issue.
Accordingly, we have proposed a phase II randomized,
blinded, placebo-controlled trial of a furosemide infu-
sion titrated to urine output in critically ill patients with
early AKI.
Objectives
The specific objectives of this trial are:
￿ To compare the efficacy and safety of a continuous
infusion of furosemide versus placebo titrated to the
physiology parameter of urine output in early AKI
on the primary outcome of progression in severity of
kidney injury from early AKI.
￿ To evaluate the impact of furosemide versus pla-
cebo on key secondary endpoints including: fluid
balance; electrolyte and acid-base balance; the need
for RRT; total duration of AKI; the rate of renal
recovery; and mortality.
￿ To evaluate the impact of furosemide versus pla-
cebo on the tertiary endpoint of differences, trajec-
tory and prognostic value of novel serum and urine
biomarkers for AKI.
Design/Methods
Study Design, Setting and Patient Population
This is a phase II randomized, blinded, placebo-con-
trolled trial of ICU patients with early AKI with rando-
mization stratified by sepsis. This study will be
performed at the University of Alberta Hospital (UAH)
General Systems Intensive Care Unit (GSICU). The
UAH is an academic/tertiary care hospital and regional
trauma centre with approximately 1300-1400 annual
admissions. All patients admitted to the GSICU will be
screened for eligibility.
Operational Definitions
Acute kidney injury (AKI)
The operational definition for early AKI will be defined
and classified according to a modified RIFLE criteria
(acronym indicating Risk of renal dysfunction; Injury to
the kidney; Failure of kidney function; Loss of kidney
function; and End-stage kidney disease) as outlined by
the ADQI Working Group [42]. In brief, the RIFLE cri-
teria classifies AKI into three categories of severity
(Risk, Injury, and Failure) and two categories of clinical
outcome (Loss and End-stage kidney disease) based on
relative changes to serum creatinine and urine output.
T h ep r e s e n c eo fe a r l yA K Iw i l lb ed e f i n e db yam i n i -
mum of RIFLE class - RISK:a na b r u p t( w i t h i n7d a y )
reduction in kidney function characterized by an relative
increase in serum creatinine of ≥ 50% (1.5 fold) or an
absolute increase of ≥ 26.5 μmol/L from baseline or a
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hours. For reference, the RIFLE category INJURY is
defined as a relative increase in serum creatinine
≥ 100% (2.0 fold) or a reduction in urine output of ≤ 0.5
mL/kg/hr for ≥ 12 hours. The RIFLE category FAILURE
is defined as a relative increase in serum creatinine
≥ 200% (3.0 fold) or an absolute value ≥354 μmol/L
(accompanied by an acute increase ≥44.2 μmol/L) or a
reduction in urine output of ≤0.3 mL/kg/hr for ≥ 24
hours or anuria for ≥ 12 hours.
Renal replacement therapy (RRT)
The operational definition of RRT will incorporate any
form of extracorporeal renal support or replacement for
patients with documented AKI. By protocol and in
order to minimize the potential bias of clinician discre-
tion on when to initiate RRT, at least one of the follow-
ing criteria must be fulfilled prior to initiation of RRT:
1) refractory oliguria (urine output <100 mL in preced-
ing 4 hrs, despite fluid resuscitation and/or vasoactive
therapy F OR maximum dose of study drug); 2) refrac-
tory extravascular fluid overload AND/OR hypoxemia
AND/OR pulmonary edema (FiO2 ≥60%, receiving
mechanical ventilation, PaO2/FiO2 ratio ≤200); 3) azote-
mia (urea ≥30 mmol/L); 4) metabolic acidosis (pH <7.2
or HCO3 <15); hyperkalemia ([K
+] ≥6.0 mmol/L or elec-
trocardiogram changes, despite maximum dose of study
drug AND/OR administration of at least 1 dose of
potassium binder AND/OR intravenous insulin AND/
OR intravenous bicarbonate; 5) uremia-induced organ
toxicity (i.e. encephalopathy, pericarditis).
Renal recovery
The operational definition of renal recovery will be the
return of serum creatinine to within 10% of baseline
levels and a spontaneous urine output ≥1.0 mL/kg/hr
for a minimum of 24 hours independent of RRT.
Systemic inflammatory response syndrome (SIRS)
The SIRS criteria include the presence of any 2 of the
following: temperature >38°C or <36°C; heart rate >90
beats/min; respiratory rate >20 breaths/min or PaCO2
<32 mmHg or mechanically ventilated; and/or white cell
count >12,000 cells/mm
3, <4,000 cells/mm
3 or with
>10% immature (band) forms[43].
Sepsis
The operational definition of the clinical syndrome of
sepsis will be the presence of confirmed or suspected
infection and the presence of ≥ 2 SIRS criteria.
Inclusion Criteria
Patients must fulfill all of the following inclusion cri-
teria:
￿ Peripheral or central intravenous catheter and
urinary catheter
￿ Early AKI
￿ ≥ 2 criteria for the systemic inflammatory response
syndrome (SIRS) within 24 hours
￿ Achieved immediate resuscitation goals (as direc-
ted by the treating physician) including fluid resusci-
tation AND/OR vasoactive therapy to achieve mean
arterial pressure ≥65 mmHg, central venous pressure
≥8 cmH2O, central venous oxygen saturation ≥70%
(if measured) AND/OR cardiac index ≥2.5 L/min/
1.73 m
2 (if measured).
Exclusion criteria
The following conditions will lead to ineligibility for
study entry:
￿ Age <18 years
￿ Confirmed or suspected pregnancy (verified by
serum [b-HCG] pregnancy test if necessary)
￿ Obstructive etiology for AKI
￿ ≥ S t a g e4c h r o n i ck i d n e yd i s e a s e( d e f i n e db ya n
estimated glomerular filtration rate <30 mL/min/
1.73 m
2), end stage kidney disease on chronic RRT,
kidney transplantation or already received RRT in
ICU
￿ Resolving AKI, defined as a ≥25% or ≥44.2 μmol/L
decline from peak increase in serum creatinine
￿ Acute pulmonary edema requiring urgent use of
furosemide or RRT or patient already receiving con-
tinuous furosemide infusion
￿ Patient is moribund with expected death within 24
hours
￿ Known or suspected drug allergy to furosemide
￿ Enrolled in concomitant randomized trial
￿ Prior enrollment in SPARK
Trial Protocol
Description of Study Flow
Figure 1 outlines the study flow. Patients will be identi-
fied in the ICU by daily surveillance by the research
coordinator or when identified by the treating ICU phy-
sician. Each patient’s eligibility will be verified by use of
a one-page checklist that summarizes the inclusion and
exclusion criteria. This checklist will be included in the
standardized case-report form (CRF).
Study Intervention
Patients will be commenced on a continuous infusion of
either the intervention (furosemide) or identical placebo
(0.9% NaCl). The study protocol for administration of
furosemide by continuous infusion is adapted from the
phase I study by Ostermann et al [44] (Figure 2).
The study infusion bag will contain 2000 mg of furo-
semide in 500 mL of 0.9%NaCl for a final concentration
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for furosemide and placebo will be identical and there
will be no marking on the infusion bags other than a 4-
digit coded identifying study number. This will minimize
bias and ensure blinding of allocation by the study
investigators, research coordinator, ICU physicians and
all involved health care providers.
The continuous infusion will be titrated to achieve a
target urine output in the range of 1.0-2.0 mL/kg/hr.
The treatment algorithm for titration of the continuous
infusion is shown in Figure 2. Each patient will be
administered a loading dose of 0.4 mg/kg as a separate
infusion bag followed by a continuous infusion com-
menced at a dose of 0.05 mg/kg/hr (Table 1). The maxi-
m u mi n f u s i o nr a t ew i l lb e0 . 4 0m g / k g / h r .T h eu r i n e
output will be assessed hourly. If the target urine output
has been achieved, then the current infusion rate will be
continued. If the target urine output has not been
achieved, the dose will be increased to the next infusion
rate in the algorithm. If the urine output is too brisk
(>2 mL/kg/hr x 2 hrs), the infusion rate will be reduced.
If the urine output is still >2 mL/kg/hr AND the
Figure 1 Overview of patient flow.
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Table 1 Summary of weight-based categories for commencement for study infusion rate (concentration study drug
4 mg/mL)
Weight Category
(kg)
Bolus loading dose Start infusion dose Start infusion dose
(mg/hr)
Start infusion rate
(mL/hr)
≤50 0.4 mg/kg 0.05 mg/kg/hr 2.5 0.6
55 0.4 mg/kg 0.05 mg/kg/hr 2.8 0.7
60 0.4 mg/kg 0.05 mg/kg/hr 3.0 0.8
65 0.4 mg/kg 0.05 mg/kg/hr 3.3 0.8
70 0.4 mg/kg 0.05 mg/kg/hr 3.5 0.9
75 0.4 mg/kg 0.05 mg/kg/hr 3.8 0.9
80 0.4 mg/kg 0.05 mg/kg/hr 4.0 1.0
85 0.4 mg/kg 0.05 mg/kg/hr 4.3 1.1
90 0.4 mg/kg 0.05 mg/kg/hr 4.5 1.1
≥95 0.4 mg/kg 0.05 mg/kg/hr 4.8 1.2
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discontinued infusion until the urine output is <1 mL/
kg/hr. If any of the following criteria are fulfilled:
decrease in mean arterial pressure <65 AND/OR addi-
tion of or an increase in vasoactive requirements of
≥20% to achieve goal mean arterial pressure OR central
venous pressure <8 cmH2O OR central venous oxygen
saturation <60% OR a cardiac index <2.0 L/min/1.73 m
2
(if measured) at any time, the consultant ICU physician
and ICU team will be notified to review the patient.
An estimate of patient ideal body weight (IBW) will be
used to determine the urine output target. Determina-
tion of estimated IBW will be based on the formula
d e s c r i b e db yD e v i n e [ 4 5 ]( T a ble 2). From this estimated
IBW, patients will be divided into 5 kg weight categories
to determine urine output goals for protocol simplicity
(Table 3). At any time during the trial, if the responsible
ICU physician believes that the administration of furose-
mide is urgently indicated (i.e. new pulmonary edema),
it can be administered and this event will be
documented.
All other aspects of patient management within the
parameters outlined (i.e. methods of fluid resuscitation,
choice of fluids, vasoactive therapy, choice of vasoactive
therapy, adjuvant therapies such as hrAPC, intensive
insulin therapy) will be at the discretion of the consultant
ICU physician. No other interventions will be performed.
The study drug infusion will be continued for a
m i n i m u mo f2 4h r sa n dd i s c o n t i n u e di fa n yo n eo ft h e
following events occurs:
￿ The patient is initiated on RRT;
￿ The patient is discharged from the ICU;
￿ The patient recovers kidney function;
￿ The patient dies;
￿ The patient develops a recognized adverse reaction
potentially related to the study infusion; or
￿ The patient has received a total of 7-days of study
drug administration.
Methods of Randomization, Concealment and Blinding
The randomization sequence will be created at a single
central location at the Epidemiology and Research Coor-
dinating Centre (EPICORE) at the University of Alberta
(available at: http://www.epicore.ualberta.ca/index.html).
This randomization sequence will be stratified by the
presence of a diagnosis of sepsis. The clinical trial phar-
macist (unblinded) will use a web-based randomization
program to determine allocation of patients and then
prepare the coded study solution. Each coded study
solution bag will then be dispensed for administration
to the patient as per protocol. This coded identifying
study number will also be labeled on the patient CRF.
The investigators, study coordinators, treating physi-
cians, bedside nurses and patients/family will remain
blinded to the allocated study solution.
Table 2 Devine formulate for ideal body weight
estimation[45].
Sex Devine Formula
Female IBW (kg) = [45 +(0.91 x (height in cm - 152))]
Male IBW (kg) = [50+ (0.91 x (height in cm - 152))]
Height
(cm)
Height
(feet)
Female Male
IBW
(kg)
Category IBW
(kg)
Category
≤152 ≤5’04 5 ≤50 50 ≤50
155 5’1 47.7 ≤50 52.7 55
157 5’2 49.6 ≤50 54.6 55
160 5’3 52.3 55 57.3 60
163 5’4 55.0 55 60.0 60
165 5’5 56.8 60 61.8 65
168 5’6 59.6 60 64.6 65
170 5’7 61.4 65 66.4 70
173 5’8 64.1 65 69.1 70
175 5’9 65.9 70 70.9 75
178 5’10 68.7 70 73.7 75
180 5’11 70.5 75 75.5 80
183 6’0 73.2 75 78.2 80
185 6’1 75.0 75 80.0 80
188 6’2 77.8 80 82.8 85
191 6’3 80.5 85 85.5 90
193 6’4 82.3 85 87.3 90
196 6’5 85.0 85 90.0 90
≥ 198 ≥ 6’6 86.9 90 91.9 95
Table 3 Summary of weight-based urine output targets.
Weight
Category
(kg)
Target Urine Output (mL)
Hourly Per 6
hours
Per 12
hours
Per 24
hours
≤50 50-100 300-600 600-1200 ≥ 1200
55 55-110 330-660 660-1320 ≥ 1320
60 60-120 360-720 720-1440 ≥ 1440
65 65-130 390-780 780-1560 ≥ 1560
70 70-140 420-840 840-1680 ≥ 1680
75 75-150 450-900 900-1800 ≥ 1800
80 80-160 480-960 960-1920 ≥ 1920
85 85-170 510-1020 1020-2040 ≥ 2040
90 90-180 540-1080 1080-2160 ≥ 2160
≥ 95 95-190 570-1140 1140-2280 ≥ 2280
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Detailed clinical, procedure-related, physiologic and
laboratory data will be collected. Blood and urine will be
collected at baseline, 12 hours, 24 hours and daily there-
after until participants exits the study. Data will be col-
lected on standardized CRFs developed by the EPICORE
centre. Completed CRF will be returned to the EPI-
CORE centre, entered into a central database, where
data queries will be generated.
Clinical data captured will include demographics, co-
morbidities and prescribed/current drug therapy. Details
of admission diagnoses, surgical status, and dates of hos-
pital and ICU admission will be recorded. Detailed data
will be recorded on date of enrollment (i.e. fulfilling cri-
teria for early AKI). This will include details of interven-
tions (i.e. mechanical ventilation, vasoactive drugs, fluid
therapy), hemodynamics (i.e. blood pressure, heart rate,
central venous pressure), and acute physiology (i.e. com-
ponents of severity of illness scores, urine output, fluid
balance, secondary non-kidney organ dysfunction). Dur-
ing the trial, data will be collected daily on urine output,
fluid balance, electrolytes, acid-base status, serum creati-
nine and urea. Collected blood and urine samples will
be stored for batched analysis of kidney-injury specific
biomarkers, including: serum and urine cystatin C,
serum and urine neutrophil gelatinase-associated lipoca-
lin (NGAL), urine interleukin-18 (IL-18); urine kidney
injury molecule-1 (KIM-1), and urine L-type fatty acid
binding protein (L-FABP).
Data will be collected each day on whether the pri-
mary endpoint (progression of AKI) has occurred, for
evidence of any secondary endpoints and for criteria for
trial discontinuation.
Finally, any study protocol violations will be recorded.
The adjudication of protocol violations will be deter-
mined by a study investigator blinded to the treatment
allocation.
All enrolled patients will be followed to determine the
duration of AKI, continued need for RRT, renal recovery
and mortality until death or discharge from hospital and
at 30, 60 and 90-days after randomization.
Sample Size Estimation
Our primary outcome measure for this trial is progres-
sion from early AKI (RIFLE class - RISK)t oam o r e
severe form of AKI, defined by progression in AKI to
the development of either RIFLE class - Injury or Fail-
ure. Based on data from a large observational study, an
estimated 60% of critically ill patients with early AKI
worsen and develop further kidney injury[46]. We esti-
mate that furosemide will contribute to a 20% absolute
reduction in the proportion of those patients who pro-
gress from early AKI (RIFLE class - RISK)t oe i t h e r
RIFLE class - Injury or Failure. This would require a
total sample size of 214 patients and provide 80% power
(alpha 0.05) for detection of a 20% difference in the pro-
portion with progression of AKI. An estimated 50% of
patients developing early AKI will have sepsis[47]. Ran-
domization will be stratified by the presence of sepsis.
The total sample size was increased to 216 patients to
ensure a balanced number of patients in each treatment
arm (Figure 1).
Statistical Analysis
The primary analysis will evaluate the proportion of cri-
tically ill patients with early AKI that have progression
in kidney injury by having received furosemide or pla-
cebo. Analysis will be intention-to-treat.
The secondary analysis will evaluate for differences
between furosemide and placebo in cumulative fluid bal-
ance and in the largest changes to serum potassium,
serum magnesium, serum pH and serum bicarbonate
levels, defined as difference from enrollment to lowest
documented level during study infusion. In addition,
this secondary analysis will evaluate for differences in
the need for RRT, duration of AKI, rate of renal recov-
ery and hospital mortality.
Descriptive statistics, boxplots and histograms will be
used to analyze individual baseline variables by having
received furosemide or placebo. Normally or near nor-
mally distributed, non-correlated variables will be
reported as means with standard deviations (SD) and
compared using the appropriate Student’stt e s t .N o n -
normally distributed, non-correlated continuous data
will be reported as medians with inter-quartile ranges
(IQR) and compared using the Mann Whitney U test.
Non-correlated categorical data, including the primary
outcome, and need for RRT, renal recovery and hospital
mortality, will be reported as proportions and compared
using Fisher’s Exact Test. If necessary, multi-variable
logistic or linear regression will be used to control for
potential confounding from imbalances in baseline char-
acteristics after randomization.
The tertiary analysis will evaluate for differences
between furosemide and placebo in the change of novel
serum and urine biomarkers for AKI, defined by abso-
lute levels and relative to baseline (enrollment) at 12
hours, 24 hours and at the time of initiation of RRT,
renal recovery or ICU discharge. All samples will remain
blinded during processing, storage and analysis. Nor-
mally distributed correlated data will be analyzed by the
repeated measures ANOVA. Non-normally distributed
c o r r e l a t e dd a t aw i l lb ea n a l y z e db yt h eF r i e d m a nt e s t .
Correlated categorical data will analyzed by generalized
estimating equations. The diagnostic and predictive
characteristics of absolute values and relative changes in
novel serum and urine biomarkers for progression of
AKI as well as need for RRT will be evaluated by 2 x 2
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tic curves. A p-value of < 0.05 will be considered signifi-
cant. All statistical tests will be two-sided.
Data Safety and Monitoring
The trial will have a data safety and monitoring commit-
t e e( D S M C )t h a tw i l lc o n s i s to ff o u rm e m b e r s .T h r e e
members will constitute a quorum. The membership
consists of persons independent of the Principal Investi-
gator who have no financial, scientific, or other conflict
of interest with the trial. Current or past collaborators
of Principal Investigator are not eligible to serve on the
DSMC. Members of the DSMC will have clinical/con-
tent expertise in acute kidney injury; clinical trial
methodology and/or biostatistics. The DSMC will meet
twice per year during the trial.
Ethical Considerations
The study has been reviewed and approved by the
Health Research Ethics Board at the University of
Alberta (File # 7362) (Additional File 1).
Potential Challenges with the Trial
Research in patients with AKI has been traditionally
challenging due to lack of a standardized definition or
classification scheme for AKI. In order to address this
issue, and optimize the potential generalizability, we
have incorporated the RIFLE definition/classification
system for AKI[42]. This consensus definition has now
been validated and its clinical use is strengthened by its
objectivity, simplicity and by the incorporation of a sys-
tem to categorize the changes in severity of AKI over
time.
The development of acute pulmonary edema in an
ICU patient with AKI was identified in our survey as an
indication for urgent furosemide or RRT and as such a
potential barrier to compliance with our trial[20]. We
have addressed this in our protocol by including a pro-
vision for the urgent use of furosemide in any enrolled
patient with pulmonary edema at the discretion of the
consultant ICU physician. Similarly, RRT can be
initiated at any time.
Another potential issue with the protocol was the
handling of an excess diuresis following initiation of the
study drug. To address this, we have incorporated into
our study algorithm provisions to temporarily discon-
tinue the study drug in the event of an excess diuresis.
Similarly, electrolyte abnormalities, in particular low
magnesium and potassium, are common with use of fur-
osemide. This issue is addressed by our ICU having
standardized protocols for the replacement of both of
these electrolytes in the event they are significantly low.
We do not anticipate any losses to follow-up during
the study intervention. This is due to our primary
outcome, progression in severity of kidney injury in
AKI, being measured while the patient is admitted to
ICU. A situation may arise where a patient is rando-
mized and allocated as non-septic but subsequently
develops sepsis during the trial. We will address this
potential issue by analyzing all these patients according
to their initial allocated group.
Discussion
Furosemide continues to be commonly used in critically
ill patients with AKI despite conflicting data on its effi-
cacy and safety from clinical studies. This observation
implies there is a misalignment between available evi-
dence and clinical practice. Moreover, this suggests
there is clinical equipoise for and there is an urgent
need to generate higher-quality evidence on the safety
and efficacy of furosemide from randomized trials to
guide on this issue. This protocol, for a phase II rando-
mized, blinded, placebo-controlled trial of a low-dose
continuous infusion of furosemide, titrated to the phy-
siology parameter of urine output, in critically ill
patients early onset AKI, proposes to inform on this
issue and potentially aid in the development, design and
conduct of a phase III trial powered to evaluate a
clinically relevant outcome such as renal replacement
therapy or mortality.
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